Indication

For the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)

Medicine details

Medicine name:
tafamidis (Vyndaqel)
SMC ID:
SMC2354
Pharmaceutical company
Pfizer Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Publication due date:
12 July 2021
SMC meeting date:
01 June 2021
Patient group submission deadline:
05 April 2021